Pharmaceutical company Merz Aesthetics has expanded its hyaluronic acid filler range in the US, announcing US Food and Drug Administration (FDA) approval for Belotero Volume and Belotero Intense.
According to the company, the additions build on Belotero Balance, which received FDA approval in 2021, aiming to create a broader portfolio of hyaluronic acid (HA) treatments designed to support personalised approaches to facial balancing, volume restoration and lip enhancement.
Merz Aesthetics says Belotero Volume incorporates its proprietary dual cross-linking technology, enabling treatment to be tailored to variations in patients’ skin tissue. The company reports that, out of 152 patients treated with Belotero Volume, 95% were satisfied with their results at 12 weeks in clinical studies.
Belotero Intense, meanwhile, was developed for patients seeking subtle lip enhancement while maintaining natural movement and expression, according to Merz Aesthetics. The company reports 100% patient satisfaction out of 165 participants in clinical data, with volume maintained for up to 12 months following treatment.
Dr Samantha Kerr, chief scientific officer at Merz Aesthetics, commented, “Belotero Volume and Belotero Intense are the culmination of years of research into how hyaluronic acid naturally behaves in skin. Developed with biomimetic design principles, these treatments are engineered to work in harmony with tissue and support natural-looking outcomes across diverse patient needs. With these two products now available alongside Belotero Balance, providers have a unified portfolio they can confidently use across the full spectrum of aesthetic goals.”